Roger Song
Stock Analyst at Jefferies
(3.25)
# 1,069
Out of 5,005 analysts
51
Total ratings
45.24%
Success rate
5.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Downgrades: Hold | $64 → $48 | $47.85 | -0.73% | 3 | Sep 9, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $451.89 | +24.81% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $2.43 | +105.76% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.83 | +1,949.18% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $16.40 | +119.51% | 1 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Hold | $3 → $1.5 | $1.62 | -7.41% | 1 | Aug 5, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $38.22 | +41.31% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $4.58 | +31.15% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.41 | -7.58% | 1 | Jun 13, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $15 → $30 | $60.91 | -50.75% | 11 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.92 | +105.48% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.15 | +68.67% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $183.66 | +33.40% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.22 | +260.11% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $5.78 | +21.12% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $9.76 | +186.89% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $1.89 | +270.37% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $69.59 | +27.89% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $9.32 | +168.38% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $9.72 | +321.81% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $23.54 | +48.68% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $42.33 | +204.75% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $3.27 | +144.65% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $85.90 | +12.92% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $31.41 | +250.21% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $3.94 | +789.45% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.35 | +566.67% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $7.13 | +12.20% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.88 | +2,277.99% | 1 | Sep 2, 2020 |
Tourmaline Bio
Sep 9, 2025
Downgrades: Hold
Price Target: $64 → $48
Current: $47.85
Upside: -0.73%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $451.89
Upside: +24.81%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $2.43
Upside: +105.76%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.83
Upside: +1,949.18%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $16.40
Upside: +119.51%
LAVA Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: $3 → $1.5
Current: $1.62
Upside: -7.41%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $38.22
Upside: +41.31%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $4.58
Upside: +31.15%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.41
Upside: -7.58%
Nektar Therapeutics
Apr 11, 2025
Upgrades: Buy
Price Target: $15 → $30
Current: $60.91
Upside: -50.75%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $2.92
Upside: +105.48%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $4.15
Upside: +68.67%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $183.66
Upside: +33.40%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.22
Upside: +260.11%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $5.78
Upside: +21.12%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $9.76
Upside: +186.89%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $1.89
Upside: +270.37%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $69.59
Upside: +27.89%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $9.32
Upside: +168.38%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $9.72
Upside: +321.81%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $23.54
Upside: +48.68%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $42.33
Upside: +204.75%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $3.27
Upside: +144.65%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $85.90
Upside: +12.92%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $31.41
Upside: +250.21%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $3.94
Upside: +789.45%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.35
Upside: +566.67%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $7.13
Upside: +12.20%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $0.88
Upside: +2,277.99%